Our top pick for
VIVUS, Inc is a biotechnology business based in the US. VIVUS shares (VVUS) are listed on the NASDAQ and all prices are listed in US Dollars. VIVUS employs 59 staff and has a trailing 12-month revenue of around USD$73.2 million.
|52-week range||USD$0.0697 - USD$1.88|
|50-day moving average||USD$0.122|
|200-day moving average||USD$0.299|
|Wall St. target price||USD$1.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.596|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing VIVUS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of VIVUS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
VIVUS's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$5.8 million.
The EBITDA is a measure of a VIVUS's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$73.2 million|
|Gross profit TTM||USD$43.8 million|
|Return on assets TTM||-2.2%|
|Return on equity TTM||0%|
|Market capitalisation||USD$8.3 million|
TTM: trailing 12 months
There are currently 3.0 million VIVUS shares held short by investors – that's known as VIVUS's "short interest". This figure is 488.8% up from 510,645 last month.
There are a few different ways that this level of interest in shorting VIVUS shares can be evaluated.
VIVUS's "short interest ratio" (SIR) is the quantity of VIVUS shares currently shorted divided by the average quantity of VIVUS shares traded daily (recently around 871468.69565217). VIVUS's SIR currently stands at 3.45. In other words for every 100,000 VIVUS shares traded daily on the market, roughly 3450 shares are currently held short.
However VIVUS's short interest can also be evaluated against the total number of VIVUS shares, or, against the total number of tradable VIVUS shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VIVUS's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 VIVUS shares in existence, roughly 170 shares are currently held short) or 0.1704% of the tradable shares (for every 100,000 tradable VIVUS shares, roughly 170 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against VIVUS.
Find out more about how you can short VIVUS stock.
We're not expecting VIVUS to pay a dividend over the next 12 months.
VIVUS's shares were split on a 1:10 basis on 11 September 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VIVUS shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for VIVUS shares which in turn could have impacted VIVUS's share price.
Over the last 12 months, VIVUS's shares have ranged in value from as little as $0.0697 up to $1.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VIVUS's is -0.8493. This would suggest that VIVUS's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, VIVUS has bucked the trend.
VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatic cancer or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, nonalcoholic steatohepatitis, and bariatric surgery; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; and Alvogen Malta Operations (ROW) Ltd. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California. On July 7, 2020, VIVUS, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.